Biotech Stocks Touching New Lows: Reliv International (NASDAQ:RELV), Can Fite Biopharma (NYSEMKT:CANF), Enzymotec (NASDAQ:ENZY), Pacific Biosciences (NASDAQ:PACB)



An increase in European and U.S. sales helped Reliv International Inc. (NASDAQ:RELV) raise profits by a small amount in the fourth quarter. Reliv International, Inc (NASDAQ:RELV) stock performance was -11.60% in last session and finished the day at $2.03. Traded volume was 64,448.00million shares in the last session and the average volume of the stock remained 10.29K shares. The beta of the stock remained 1.35. Reliv International, Inc (NASDAQ:RELV) insider ownership is 36.99%.

Can-Fite BioPharma Ltd. (ADR) (AMEX:CANF) announced that it has closed a private placement with mostly US healthcare focused institutional investors resulting in gross proceeds of $5 million. Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) dropped -5.47 percent to $5.53 yesterday on volume of 24.82K shares. Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF) has a market capitalization of $37.55million.

Enzymotec Ltd (NASDAQ:ENZY) sports a Zacks Rank #1 (Strong Buy), Covidien and Stryker bear a Zacks Rank #2 (Buy). Enzymotec Ltd (NASDAQ:ENZY)’s stock on Mar 10, 2014 reported a decrease of -5.94% to the closing price of $25.96. Its fifty two weeks range is $14.25 -$35.12. The total market capitalization recorded $564.90million. The overall volume in the last trading session was 157,278.00million shares. In its share capital, ENZY has 21.55million outstanding shares.

Pacific Biosciences of California (NASDAQ:PACB) has been awarded US Patent No. 8,658,365, “Nucleic acid synthesis compositions and methods and systems for using same.” On Monday, shares of Pacific Biosciences of California (NASDAQ:PACB) dropped -6.97% to close the day at $6.20. Company return on investment (ROI) is -91.00% and its monthly performance is recorded as -1.97%. Pacific Biosciences of California (NASDAQ:PACB) quarterly revenue growth is 41.02%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone